Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2 View Homepage


Ontology type: schema:MedicalStudy     


Clinical Trial Info

YEARS

2014-2021

ABSTRACT

Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at 14 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes. Detailed Description Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD therapies for new clinical trials. The FTLD CRC will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Patients will be evaluated at 13 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes. The study will be divided into 2 projects. The first project will be Preparing for Sporadic FTLD Clinical Trials and the second project will be a Longitudinal Assessment of Familial FTLD. Self-registration for an online registry will be available for patients and families with any FTLD syndrome. Eligible participants for research Projects 1 and 2 FTLD will be invited to a CRC site for clinical evaluations. All enrolled participants in both research projects will have a site visit consisting of a neurological exam, medical and family history, cognitive testing, and a blood draw. Participants in Project 1 who have a diagnosis of Progressive Supranuclear Palsy Syndrome will have two additional assessments. A lumbar puncture (LP) will be performed for CSF collection, and an MRI scan of the brain will be done. Participants in Project 2: Longitudinal Assessment of familial FTLD will return for a follow-up visit in 12 months; procedures at the follow-up visit will be identical to those at baseline. Additionally, asymptomatic participants will undergo MRI scans at both visits. More... »

URL

https://clinicaltrials.gov/show/NCT02365922

Related SciGraph Publications

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/3120", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "type": "DefinedTerm"
      }
    ], 
    "description": "Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at 14 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes.\n\nDetailed Description\nFrontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD therapies for new clinical trials. The FTLD CRC will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Patients will be evaluated at 13 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes. The study will be divided into 2 projects. The first project will be Preparing for Sporadic FTLD Clinical Trials and the second project will be a Longitudinal Assessment of Familial FTLD. Self-registration for an online registry will be available for patients and families with any FTLD syndrome. Eligible participants for research Projects 1 and 2 FTLD will be invited to a CRC site for clinical evaluations. All enrolled participants in both research projects will have a site visit consisting of a neurological exam, medical and family history, cognitive testing, and a blood draw. Participants in Project 1 who have a diagnosis of Progressive Supranuclear Palsy Syndrome will have two additional assessments. A lumbar puncture (LP) will be performed for CSF collection, and an MRI scan of the brain will be done. Participants in Project 2: Longitudinal Assessment of familial FTLD will return for a follow-up visit in 12 months; procedures at the follow-up visit will be identical to those at baseline. Additionally, asymptomatic participants will undergo MRI scans at both visits.", 
    "endDate": "2021-02-01T00:00:00Z", 
    "id": "sg:clinicaltrial.NCT02365922", 
    "keywords": [
      "rare disease", 
      "frontotemporal lobar degeneration", 
      "research project", 
      "collection", 
      "neurodegenerative disease", 
      "clinical syndrome", 
      "frontotemporal dementia", 
      "Primary progressive aphasia", 
      "corticobasal degeneration", 
      "progressive supranuclear palsy", 
      "development", 
      "clinical trial", 
      "UCSF", 
      "partner", 
      "patient advocacy group", 
      "consortium", 
      "clinical site", 
      "North America", 
      "Genetics Core", 
      "genotype", 
      "individual", 
      "patient", 
      "first project", 
      "second project", 
      "longitudinal assessment", 
      "registration", 
      "registry", 
      "family", 
      "eligible participant", 
      "Research", 
      "CRC", 
      "clinical evaluation", 
      "enrolled participant", 
      "site visit", 
      "neurological exam", 
      "family history", 
      "cognitive testing", 
      "blood", 
      "project 1", 
      "diagnosis", 
      "additional assessment", 
      "Spinal Puncture", 
      "MRI", 
      "brain", 
      "project 2", 
      "follow-up visit", 
      "method", 
      "baseline", 
      "visit"
    ], 
    "name": "Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2", 
    "sameAs": [
      "https://app.dimensions.ai/details/clinical_trial/NCT02365922"
    ], 
    "sdDataset": "clinical_trials", 
    "sdDatePublished": "2019-03-07T15:25", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "file:///pack/app/us_ct_data_00018.json", 
    "sponsor": [
      {
        "id": "https://www.grid.ac/institutes/grid.17091.3e", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.25879.31", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.16753.36", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.265892.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.412618.8", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.266102.1", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.429651.d", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.21107.35", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.4367.6", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.443867.a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.17063.33", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.416870.c", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.21729.3f", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.417467.7", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.410711.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.267313.2", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.19006.3e", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.32224.35", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.66875.3a", 
        "type": "Organization"
      }, 
      {
        "id": "https://www.grid.ac/institutes/grid.266100.3", 
        "type": "Organization"
      }
    ], 
    "startDate": "2014-09-01T00:00:00Z", 
    "subjectOf": [
      {
        "id": "https://doi.org/10.1001/archneurol.2011.1021", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1016453017"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.3109/09540261.2013.778822", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1018398858"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1353-8020(11)70060-8", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020877809"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(14)70088-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1025984792"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.neuroimage.2009.11.041", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034808010"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(12)70320-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1037888264"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1037/neu0000012", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047037549"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s12031-011-9624-1", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1051095082", 
          "https://doi.org/10.1007/s12031-011-9624-1"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "type": "MedicalStudy", 
    "url": "https://clinicaltrials.gov/show/NCT02365922"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/clinicaltrial.NCT02365922'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/clinicaltrial.NCT02365922'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/clinicaltrial.NCT02365922'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/clinicaltrial.NCT02365922'


 

This table displays all metadata directly associated to this object as RDF triples.

131 TRIPLES      16 PREDICATES      91 URIs      58 LITERALS      1 BLANK NODES

Subject Predicate Object
1 sg:clinicaltrial.NCT02365922 schema:about anzsrc-for:3120
2 schema:description Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium to support the development of FTLD therapies for new clinical trials. The consortium, referred to as Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL), will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Participants will be evaluated at 14 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes. Detailed Description Frontotemporal Lobar Degeneration (FTLD) is the neuropathological term for a collection of rare neurodegenerative diseases that correspond to four main overlapping clinical syndromes: frontotemporal dementia (FTD), primary progressive aphasia (PPA), corticobasal degeneration syndrome (CBS) and progressive supranuclear palsy syndrome (PSPS). The goal of this study is to build a FTLD clinical research consortium (FTLD CRC) to support the development of FTLD therapies for new clinical trials. The FTLD CRC will be headquartered at UCSF and will partner with six patient advocacy groups to manage the consortium. Patients will be evaluated at 13 clinical sites throughout North America and a genetics core will genotype all individuals for FTLD associated genes. The study will be divided into 2 projects. The first project will be Preparing for Sporadic FTLD Clinical Trials and the second project will be a Longitudinal Assessment of Familial FTLD. Self-registration for an online registry will be available for patients and families with any FTLD syndrome. Eligible participants for research Projects 1 and 2 FTLD will be invited to a CRC site for clinical evaluations. All enrolled participants in both research projects will have a site visit consisting of a neurological exam, medical and family history, cognitive testing, and a blood draw. Participants in Project 1 who have a diagnosis of Progressive Supranuclear Palsy Syndrome will have two additional assessments. A lumbar puncture (LP) will be performed for CSF collection, and an MRI scan of the brain will be done. Participants in Project 2: Longitudinal Assessment of familial FTLD will return for a follow-up visit in 12 months; procedures at the follow-up visit will be identical to those at baseline. Additionally, asymptomatic participants will undergo MRI scans at both visits.
3 schema:endDate 2021-02-01T00:00:00Z
4 schema:keywords CRC
5 Genetics Core
6 MRI
7 North America
8 Primary progressive aphasia
9 Research
10 Spinal Puncture
11 UCSF
12 additional assessment
13 baseline
14 blood
15 brain
16 clinical evaluation
17 clinical site
18 clinical syndrome
19 clinical trial
20 cognitive testing
21 collection
22 consortium
23 corticobasal degeneration
24 development
25 diagnosis
26 eligible participant
27 enrolled participant
28 family
29 family history
30 first project
31 follow-up visit
32 frontotemporal dementia
33 frontotemporal lobar degeneration
34 genotype
35 individual
36 longitudinal assessment
37 method
38 neurodegenerative disease
39 neurological exam
40 partner
41 patient
42 patient advocacy group
43 progressive supranuclear palsy
44 project 1
45 project 2
46 rare disease
47 registration
48 registry
49 research project
50 second project
51 site visit
52 visit
53 schema:name Rare Diseases Clinical Research Network Advancing Research and Treatment for Frontotemporal Lobar Degeneration [ARTFL]: Research Projects 1 & 2
54 schema:sameAs https://app.dimensions.ai/details/clinical_trial/NCT02365922
55 schema:sdDatePublished 2019-03-07T15:25
56 schema:sdLicense https://scigraph.springernature.com/explorer/license/
57 schema:sdPublisher N4e38c6a652e54d49a5ff436c965355da
58 schema:sponsor https://www.grid.ac/institutes/grid.16753.36
59 https://www.grid.ac/institutes/grid.17063.33
60 https://www.grid.ac/institutes/grid.17091.3e
61 https://www.grid.ac/institutes/grid.19006.3e
62 https://www.grid.ac/institutes/grid.21107.35
63 https://www.grid.ac/institutes/grid.21729.3f
64 https://www.grid.ac/institutes/grid.25879.31
65 https://www.grid.ac/institutes/grid.265892.2
66 https://www.grid.ac/institutes/grid.266100.3
67 https://www.grid.ac/institutes/grid.266102.1
68 https://www.grid.ac/institutes/grid.267313.2
69 https://www.grid.ac/institutes/grid.32224.35
70 https://www.grid.ac/institutes/grid.410711.2
71 https://www.grid.ac/institutes/grid.412618.8
72 https://www.grid.ac/institutes/grid.416870.c
73 https://www.grid.ac/institutes/grid.417467.7
74 https://www.grid.ac/institutes/grid.429651.d
75 https://www.grid.ac/institutes/grid.4367.6
76 https://www.grid.ac/institutes/grid.443867.a
77 https://www.grid.ac/institutes/grid.66875.3a
78 schema:startDate 2014-09-01T00:00:00Z
79 schema:subjectOf sg:pub.10.1007/s12031-011-9624-1
80 https://doi.org/10.1001/archneurol.2011.1021
81 https://doi.org/10.1016/j.neuroimage.2009.11.041
82 https://doi.org/10.1016/s1353-8020(11)70060-8
83 https://doi.org/10.1016/s1474-4422(12)70320-4
84 https://doi.org/10.1016/s1474-4422(14)70088-2
85 https://doi.org/10.1037/neu0000012
86 https://doi.org/10.3109/09540261.2013.778822
87 schema:url https://clinicaltrials.gov/show/NCT02365922
88 sgo:license sg:explorer/license/
89 sgo:sdDataset clinical_trials
90 rdf:type schema:MedicalStudy
91 N4e38c6a652e54d49a5ff436c965355da schema:name Springer Nature - SN SciGraph project
92 rdf:type schema:Organization
93 anzsrc-for:3120 schema:inDefinedTermSet anzsrc-for:
94 rdf:type schema:DefinedTerm
95 sg:pub.10.1007/s12031-011-9624-1 schema:sameAs https://app.dimensions.ai/details/publication/pub.1051095082
96 https://doi.org/10.1007/s12031-011-9624-1
97 rdf:type schema:CreativeWork
98 https://doi.org/10.1001/archneurol.2011.1021 schema:sameAs https://app.dimensions.ai/details/publication/pub.1016453017
99 rdf:type schema:CreativeWork
100 https://doi.org/10.1016/j.neuroimage.2009.11.041 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034808010
101 rdf:type schema:CreativeWork
102 https://doi.org/10.1016/s1353-8020(11)70060-8 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020877809
103 rdf:type schema:CreativeWork
104 https://doi.org/10.1016/s1474-4422(12)70320-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1037888264
105 rdf:type schema:CreativeWork
106 https://doi.org/10.1016/s1474-4422(14)70088-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1025984792
107 rdf:type schema:CreativeWork
108 https://doi.org/10.1037/neu0000012 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047037549
109 rdf:type schema:CreativeWork
110 https://doi.org/10.3109/09540261.2013.778822 schema:sameAs https://app.dimensions.ai/details/publication/pub.1018398858
111 rdf:type schema:CreativeWork
112 https://www.grid.ac/institutes/grid.16753.36 schema:Organization
113 https://www.grid.ac/institutes/grid.17063.33 schema:Organization
114 https://www.grid.ac/institutes/grid.17091.3e schema:Organization
115 https://www.grid.ac/institutes/grid.19006.3e schema:Organization
116 https://www.grid.ac/institutes/grid.21107.35 schema:Organization
117 https://www.grid.ac/institutes/grid.21729.3f schema:Organization
118 https://www.grid.ac/institutes/grid.25879.31 schema:Organization
119 https://www.grid.ac/institutes/grid.265892.2 schema:Organization
120 https://www.grid.ac/institutes/grid.266100.3 schema:Organization
121 https://www.grid.ac/institutes/grid.266102.1 schema:Organization
122 https://www.grid.ac/institutes/grid.267313.2 schema:Organization
123 https://www.grid.ac/institutes/grid.32224.35 schema:Organization
124 https://www.grid.ac/institutes/grid.410711.2 schema:Organization
125 https://www.grid.ac/institutes/grid.412618.8 schema:Organization
126 https://www.grid.ac/institutes/grid.416870.c schema:Organization
127 https://www.grid.ac/institutes/grid.417467.7 schema:Organization
128 https://www.grid.ac/institutes/grid.429651.d schema:Organization
129 https://www.grid.ac/institutes/grid.4367.6 schema:Organization
130 https://www.grid.ac/institutes/grid.443867.a schema:Organization
131 https://www.grid.ac/institutes/grid.66875.3a schema:Organization
 




Preview window. Press ESC to close (or click here)


...